Detroit/ Science, Tech & Medicine

Macomb County Woman, 71, Gets Michigan's First Vagus Nerve Implant for Arthritis

AI Assisted Icon
Published on November 21, 2026
Macomb County Woman, 71, Gets Michigan's First Vagus Nerve Implant for ArthritisMacomb County — Landrith's Home County
Google Street View

Kim Landrith has spent nearly 30 years fighting rheumatoid arthritis, cycling through oral medications, injections, infusion therapy and home remedies, and undergoing joint replacement surgeries on her knees, shoulders and hip. On October 26, the 71-year-old Macomb County resident became the first person in Michigan to receive a newly approved implant that stimulates the vagus nerve to help calm the disease, a procedure performed at Henry Ford Hospital in Detroit.

The device, called the SetPoint System, was developed by California-based SetPoint Medical and is the first FDA-approved device of its kind for adults with moderate to severe rheumatoid arthritis, according to Eurasia Review. The system is intended for patients who have responded inadequately to their medications or who cannot tolerate them. Rheumatoid arthritis is a chronic autoimmune disease that can damage joints and limit mobility, and it affects about 1.5 million people in the United States, per the same report.

A Procedure Lasting Barely an Hour

Dr. Ellen Air, a Henry Ford Health functional neurosurgeon and chair of the health system's Department of Neurosurgery, completed the implantation. The outpatient procedure took roughly 60 to 90 minutes and involved a small incision along a crease in the neck, placing the device on the left vagus nerve before Landrith returned home the same day, Eurasia Review reports.

The device itself is about the size of a multivitamin. Once activated, it delivers daily electrical stimulation, running for one minute each day, intended to reduce the inflammation driving rheumatoid arthritis. Patients recharge it weekly using a charger worn around the neck, and the system is designed to last up to 10 years. Landrith's device was not switched on immediately; the SetPoint System is typically activated a few weeks after implantation once the incision has healed, and hers was activated on November 11.

Decades of Treatment, A New Option

“Vagus nerve stimulation has been used for years to treat epilepsy and to aid in stroke recovery, and now it's being applied to rheumatoid arthritis,” Dr. Air said, according to Eurasia Review. She added that the therapy may offer relief for patients whose rheumatoid arthritis medications have not helped them.

Landrith said she hopes the implant brings her greater mobility and less pain, with goals as specific as being able to write her name again and walk without pain in her toes and feet, per the same account. Eligible patients are typically referred by their rheumatologist to a neurosurgeon, and those interested in the SetPoint System are encouraged to discuss eligibility and possible referral with Henry Ford Health neurosurgery, the outlet reports.

What the Clinical Trial Found

The device's approval rests on the RESET-RA trial, which tested the system in 242 adults with moderately to severely active rheumatoid arthritis who had an inadequate response, loss of response, or intolerance to at least one biologic or targeted synthetic disease-modifying antirheumatic drug, according to a SetPoint Medical announcement. At three months, ACR20 response rates were higher with active stimulation than with a sham procedure, 35.2% versus 24.2%, according to findings published in Nature Medicine. Response rates climbed further in the trial's open-label phase, reaching 50.0% at six months and 52.8% at 12 months among all completers, per the same study. The journal also reported that related serious adverse events occurred at a rate of 1.6%, all of them perioperative and all resolved.

Longer-term results have continued to roll in. At 12 months, 75.2% of patients had not needed an adjunctive biologic or JAK inhibitor added to their stimulation therapy, according to SetPoint Medical. By the 24-month mark, announced November 9, 71% of participants had reached that follow-up point without adding one of those drugs, and 91.7% of participants were still using the stimulation therapy, with just 29.3% combining it with a biologic or targeted synthetic DMARD, the company reported. A cost analysis co-authored by Dr. Air projected lifetime health care savings exceeding $350,000 per patient compared with medication alone, Eurasia Review reports.

Expanding Beyond Michigan

Michigan is one of a growing number of states where the device has become available. SetPoint Medical has said the system was available in select U.S. markets as of January, with broader national expansion planned throughout the year. The company also announced that Boston had joined that list of markets after the first patient there received the implant at Beth Israel Deaconess Medical Center on October 28, just two days after Landrith's procedure in Detroit.

The FDA notice for the device's premarket approval application lists July 30, 2025, as the approval date, according to FDA records. For Landrith, the science behind the approval matters less than what it might mean day to day — a chance, after three decades of pain, at writing her name without wincing.

Detroit-Science, Tech & Medicine